肿瘤细胞治疗研究
英文原题：CAR-T Therapy Can Be a Useful Treatment Modality for More Than Just Hematologic Malignancies.
CAR-T Therapy Can Be a Useful Treatment Modality for More Than Just Hematologic Malignancies.
血液系统恶性肿瘤的CAR-T 细胞疗法多年来取得了显著进展，现已被纳入治疗流程。
用于血液系统恶性肿瘤的CAR-T 细胞疗法近年来取得显著进展，现已纳入治疗流程。多种实体瘤的早期临床试验正在开展；CAR-T疗法对特定类型胶质瘤及若干其他实体瘤已显示疗效，但效果仍不及血液系统恶性肿瘤。近期病例系列报告显示，靶向CD19的CAR-T细胞治疗系统性红斑狼疮等自身免疫病，可显著改善临床症状，并可能停用免疫抑制药物。此外，CAR-T疗法有望用于治疗多种病毒及曲霉菌属感染。研究者也尝试将CAR构建体导入调节性T细胞，以靶向其免疫抑制作用。本文介绍CAR-T治疗突破血液系统恶性肿瘤领域后的当前进展，并结合日本当前医疗环境讨论未来方向。
Chimeric antigen receptor-T-cell (CAR-T) therapy for hematologic malignancies has made significant advancements over the years, and it is now incorporated as a treatment algorithm. Early phase clinical trials are underway for various solid tumors, and the effectiveness of CAR-T cell therapy has been demonstrated for specific types of glioma and several solid tumors. However, its efficacy does not match that observed in hematological malignancies. Recently, a case series reported CAR-T cell therapy targeting CD19 for autoimmune diseases such as systemic lupus erythematosus, leading to a dramatic improvement in the clinical symptoms and the possibility of discontinuing immunosuppressive agents. Furthermore, CAR-T cell therapy is expected to be effective against various viruses and Aspergillus spp. Finally, attempts have been made to introduce CAR constructs into regulatory T cells to target their immunosuppressive effects. This article introduces the current progress in CAR-T cell therapy beyond the treatment of only hematologic malignancies and discusses future directions, considering the current medical situation in Japan.
MEMBER ACCOUNT
登录成功会直接打开下一页。
